Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

102.20
+1.141.13%
Post-market: 102.200.00000.00%16:11 EDT
Volume:422.88K
Turnover:43.13M
Market Cap:7.04B
PE:-32.79
High:102.89
Open:99.88
Low:99.88
Close:101.06
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:0.97
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:68.33
PE(LYR):-32.86

Loading ...

Rhythm Pharmaceuticals Q2 Net Income USD -49.298 Million Vs. IBES Estimate USD -55.5 Million

Reuters
·
Aug 04

Rhythm Pharmaceuticals Q2 Basic EPS USD -0.73

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Estimates Non-Gaap Operating Expenses $363 Mln-$397 Mln for Year Ending Dec 31, 2026

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial That Showed Rm-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Two Participants Discontinued Rm-718 Treatment Due to Adverse Events

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Reports 11.6% Mean Bmi Reduction at Week 16 in Phase 2 Rm-718 Trial

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Rm-718 Generally Well Tolerated with Most Common Adverse Events Injection Site Reactions, Nausea, Vomiting

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Reports Two Mild Cases of Injection Site Hyperpigmentation in Rm-718 Trial

THOMSON REUTERS
·
Aug 04

Rhythm Pharmaceuticals - Eight Patients Remain on Active Treatment as of July 16, 2026

THOMSON REUTERS
·
Aug 04

Earning Preview: Rhythm Pharmaceuticals Inc. Q2 revenue is expected to increase by 54.19%, and institutional views are bullish

Earnings Agent
·
Jul 29

Rhythm Pharmaceuticals (RYTM) Faces A Big Undervaluation Call, Is The Upside Already Priced In?

Simply Wall St.
·
Jul 27

Wells Fargo Releases a Buy Rating on Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Jul 16

Rhythm’s Setmelanotide Extension Study: What Long-Term Data Could Mean for RYTM

TIPRANKS
·
Jul 16

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Jul 15

Does NEJM-Validated TRANSCEND Data on Setmelanotide Reshape the Bull Case for Rhythm Pharmaceuticals (RYTM)?

Simply Wall St.
·
Jul 13

Rhythm Pharmaceuticals Announces the New England Journal of Medicine Publication of Phase 3 Transcend Trial Results in Acquired Hypothalamic Obesity

THOMSON REUTERS
·
Jul 09

Medicare Coverage Could Put These Obesity Drug Stocks In Focus

Simply Wall St.
·
Jun 30

Rhythm Pharmaceuticals on Track for Highest Close Since January

Dow Jones
·
Jun 25

Rhythm Pharma Director Lynn A. Tetrault Disposes of Common Shares Worth $3.71 Million

Reuters
·
Jun 25

Rhythm Pharmaceuticals (RYTM) Stock Could Be 30.6% Undervalued on Its Growth Narrative

Simply Wall St.
·
Jun 22